| Year |
Citation |
Score |
| 2023 |
Thomas S, Prendergast GC. Gut-brain connections in neurodegenerative disease: immunotherapeutic targeting of Bin1 in inflammatory bowel disease and Alzheimer's disease. Frontiers in Pharmacology. 14: 1183932. PMID 37521457 DOI: 10.3389/fphar.2023.1183932 |
0.542 |
|
| 2023 |
Thomas S, Dilbarov N, Kelly J, Mercogliano G, Prendergast GC. Diet effects on colonic health influence the efficacy of Bin1 mAb immunotherapy for ulcerative colitis. Scientific Reports. 13: 11802. PMID 37479833 DOI: 10.1038/s41598-023-38830-2 |
0.541 |
|
| 2023 |
Muller AJ, Thomas S, Prendergast GC. A Brief Overview of Cancer Vaccines. Cancer Journal (Sudbury, Mass.). 29: 34-37. PMID 36693156 DOI: 10.1097/PPO.0000000000000640 |
0.574 |
|
| 2022 |
Thomas S, Mercogliano G, Prendergast GC. Bin1 targeted immunotherapy alters the status of the enteric neurons and the microbiome during ulcerative colitis treatment. Plos One. 17: e0276910. PMID 36322599 DOI: 10.1371/journal.pone.0276910 |
0.566 |
|
| 2021 |
Dey S, Mondal A, DuHadaway JB, Sutanto-Ward E, Laury-Kleintop LD, Thomas S, Prendergast GC, Mandik-Nayak L, Muller AJ. IDO1 Signaling Through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization. Cancer Immunology Research. PMID 33622713 DOI: 10.1158/2326-6066.CIR-20-0226 |
0.622 |
|
| 2020 |
Merlo LMF, DuHadaway JB, Montgomery JD, Peng WD, Murray PJ, Prendergast GC, Caton AJ, Muller AJ, Mandik-Nayak L. Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses. Frontiers in Immunology. 11: 1861. PMID 32973768 DOI: 10.3389/Fimmu.2020.01861 |
0.369 |
|
| 2020 |
Dey S, Mondal A, DuHadaway JB, Sutanto-Ward E, Laury-Kleintop L, Thomas S, Prendergast GC, Mandik-Nayak L, Muller AJ. Abstract 1474: IDO1 signaling supports inflammatory neovascularization Cancer Research. 80: 1474-1474. DOI: 10.1158/1538-7445.Am2020-1474 |
0.657 |
|
| 2019 |
Thomas S, Laury-Kleintop L, Prendergast GC. Reliable detection of indoleamine 2,3 dioxygenase-1 in murine cells and tissues. Methods in Enzymology. 629: 219-233. PMID 31727242 DOI: 10.1016/Bs.Mie.2019.08.008 |
0.614 |
|
| 2019 |
Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LMF, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. International Immunology. 31: 181-182. PMID 31222337 DOI: 10.1093/Intimm/Dxz003 |
0.34 |
|
| 2019 |
Thomas S, Hoxha K, Tran A, Prendergast GC. Bin1 antibody lowers the expression of phosphorylated Tau in Alzheimer's disease. Journal of Cellular Biochemistry. PMID 31211444 DOI: 10.1002/Jcb.29142 |
0.613 |
|
| 2019 |
Manley K, Bravo-Nuevo A, Minton AR, Sedano S, Marcy A, Reichman M, Tobia A, Artlett CM, Gilmour SK, Laury-Kleintop LD, Prendergast GC. Preclinical study of the long-range safety and anti-inflammatory effects of high-dose oral meglumine. Journal of Cellular Biochemistry. PMID 30809852 DOI: 10.1002/Jcb.28492 |
0.728 |
|
| 2019 |
Lemos H, Huang L, Prendergast GC, Mellor AL. Immune control by amino acid catabolism during tumorigenesis and therapy. Nature Reviews. Cancer. PMID 30696923 DOI: 10.1038/S41568-019-0106-Z |
0.375 |
|
| 2019 |
Prendergast GC, Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis M, Villatoro T, Leiby BE, Winter JM, et al. Abstract A101: IDO2 host genetic status influences progression and radiotherapy response in pancreatic ductal adenocarcinoma Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A101 |
0.332 |
|
| 2018 |
Almonte-Baldonado R, Bravo-Nuevo A, Gerald D, Benjamin LE, Prendergast GC, Laury-Kleintop LD. RhoB antibody alters retinal vascularization in models of murine retinopathy. Journal of Cellular Biochemistry. PMID 30536763 DOI: 10.1002/Jcb.28213 |
0.732 |
|
| 2018 |
Winters M, DuHadaway JB, Pham KN, Lewis-Ballester A, Badir S, Wai J, Sheikh E, Yeh SR, Prendergast GC, Muller AJ, Malachowski WP. Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. European Journal of Medicinal Chemistry. 162: 455-464. PMID 30469041 DOI: 10.1016/J.Ejmech.2018.11.010 |
0.308 |
|
| 2018 |
Thomas S, Hoxha K, Alexander W, Gilligan J, Dilbarova R, Whittaker K, Kossenkov A, Prendergast GC, Mullin JM. Intestinal barrier tightening by a cell-penetrating antibody to Bin1, a candidate target for immunotherapy of ulcerative colitis. Journal of Cellular Biochemistry. PMID 30269357 DOI: 10.1002/Jcb.27716 |
0.639 |
|
| 2018 |
Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis MT, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, ... ... Prendergast GC, et al. Host gene status influences tumor progression and radiotherapy response in -driven sporadic pancreatic cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30266763 DOI: 10.1158/1078-0432.Ccr-18-0814 |
0.341 |
|
| 2018 |
Fox E, Oliver T, Rowe M, Thomas S, Zakharia Y, Gilman PB, Muller AJ, Prendergast GC. Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Frontiers in Oncology. 8: 370. PMID 30254983 DOI: 10.3389/Fonc.2018.00370 |
0.633 |
|
| 2018 |
Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Seminars in Immunopathology. PMID 30203227 DOI: 10.1007/S00281-018-0702-0 |
0.318 |
|
| 2018 |
Prendergast GC, Malachowski WJ, Mondal A, Scherle P, Muller AJ. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. International Review of Cell and Molecular Biology. 336: 175-203. PMID 29413890 DOI: 10.1016/Bs.Ircmb.2017.07.004 |
0.401 |
|
| 2018 |
Prendergast GC, Mondal A, Dey S, Laury-Kleintop LD, Muller AJ. Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. Trends in Cancer. 4: 38-58. PMID 29413421 DOI: 10.1016/J.Trecan.2017.11.005 |
0.339 |
|
| 2018 |
Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, ... ... Prendergast GC, et al. CCR5 governs DNA damage and breast cancer stem cell expansion. Cancer Research. PMID 29358169 DOI: 10.1158/0008-5472.Can-17-0915 |
0.405 |
|
| 2018 |
Thomas S, Hoxha K, Kaufman A, Mullin JM, Prendergast G. Tu1742 - BIN1 Mab as a Novel Immunotherapy for the Treatment of Ulcerative Colitis Gastroenterology. 154: S-1007. DOI: 10.1016/S0016-5085(18)33368-7 |
0.566 |
|
| 2017 |
Thomas S, Izard J, Walsh E, Batich K, Chongsathidkiet P, Clarke G, Sela DA, Muller AJ, Mullin JM, Albert K, Gilligan JP, DiGuilio K, Dilbarova R, Alexander W, Prendergast GC. The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. Cancer Research. PMID 28292977 DOI: 10.1158/0008-5472.Can-16-2929 |
0.618 |
|
| 2017 |
Merlo LM, Grabler S, DuHadaway JB, Pigott E, Manley K, Prendergast GC, Laury-Kleintop LD, Mandik-Nayak L. Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis. Clinical Immunology (Orlando, Fla.). PMID 28223071 DOI: 10.1016/J.Clim.2017.01.016 |
0.335 |
|
| 2017 |
Mondal A, Sutanto-Ward E, DuHadaway JB, Bravo-Nuevo A, Thomas S, Prendergast GC, Muller AJ. Abstract 2680: A novel pro-tumorigenic role for IDO1 in inflammatory neovascularization Immunology. 77: 2680-2680. DOI: 10.1158/1538-7445.Am2017-2680 |
0.589 |
|
| 2016 |
Mondal A, Smith C, DuHadaway JB, Sutanto-Ward E, Prendergast GC, Bravo-Nuevo A, Muller AJ. IDO1 is an Integral Mediator of Inflammatory Neovascularization. Ebiomedicine. PMID 27889479 DOI: 10.1016/J.Ebiom.2016.11.013 |
0.754 |
|
| 2016 |
Merlo LM, DuHadaway JB, Grabler S, Prendergast GC, Muller AJ, Mandik-Nayak L. IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism. Journal of Immunology (Baltimore, Md. : 1950). PMID 27183624 DOI: 10.4049/Jimmunol.1600141 |
0.368 |
|
| 2016 |
Thomas S, Prendergast GC. Cancer Vaccines: A Brief Overview. Methods in Molecular Biology (Clifton, N.J.). 1403: 755-61. PMID 27076165 DOI: 10.1007/978-1-4939-3387-7_43 |
0.599 |
|
| 2016 |
DuHadaway J, Prendergast GC. Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancer. Oncotarget. 7: 7372-80. PMID 26840263 DOI: 10.18632/Oncotarget.7058 |
0.363 |
|
| 2016 |
Kumari A, Iwasaki T, Folk WP, Abdulovic-Cui AL, Pyndiah S, Prendergast GC, Sedivy JM, Sakamuro D. Abstract PR09: c-MYC preserves genomic integrity during DNA replication: a paradigm shift of c-MYC Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Cellcycle16-Pr09 |
0.699 |
|
| 2015 |
Bravo-Nuevo A, Brandli AA, Gerhart J, Nichols J, Pitts M, Sutera CK, Assali S, Scheinfeld V, Prendergast GC, Stone J, George-Weinstein M. Neuroprotective Effect of Myo/Nog Cells in the Stressed Retina. Experimental Eye Research. PMID 26688580 DOI: 10.1016/J.Exer.2015.11.023 |
0.757 |
|
| 2015 |
Thomas S, Mercado JM, DuHadaway J, DiGuilio K, Mullin JM, Prendergast GC. Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function. Digestive Diseases and Sciences. PMID 26195312 DOI: 10.1007/S10620-015-3804-8 |
0.606 |
|
| 2015 |
Wallon UM, Sabol JL, Zemba-Palko V, DuHadaway JS, Sutanto-Ward E, Ali ZA, Gilman PB, Ciocca RM, Carp NZ, Prendergast GC. Abstract P6-08-54: TIMP-4 is a prognostic and predictive marker in triple-negative breast cancers Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-08-54 |
0.392 |
|
| 2015 |
Mondal A, DuHadaway JB, Sutanto-Ward E, Smith C, Prendergast GC, Bravo-Nuevo A, Muller AJ. Abstract 5223: A novel pro-angiogenic role for IDO1 in inflammatory tumor promotion Cancer Research. 75: 5223-5223. DOI: 10.1158/1538-7445.Am2015-5223 |
0.768 |
|
| 2014 |
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, ... ... Prendergast GC, et al. Classification of current anticancer immunotherapies. Oncotarget. 5: 12472-508. PMID 25537519 DOI: 10.18632/Oncotarget.2998 |
0.321 |
|
| 2014 |
Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L. IDO2 in Immunomodulation and Autoimmune Disease. Frontiers in Immunology. 5: 585. PMID 25477879 DOI: 10.3389/Fimmu.2014.00585 |
0.371 |
|
| 2014 |
Pigott E, DuHadaway JB, Muller AJ, Gilmour S, Prendergast GC, Mandik-Nayak L. 1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity. 47: 409-18. PMID 24798341 DOI: 10.3109/08916934.2014.914507 |
0.316 |
|
| 2014 |
Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunology, Immunotherapy : Cii. 63: 721-35. PMID 24711084 DOI: 10.1007/S00262-014-1549-4 |
0.671 |
|
| 2014 |
Bravo-Nuevo A, Marcy A, Huang M, Kappler F, Mulgrew J, Laury-Kleintop L, Reichman M, Tobia A, Prendergast GC. Meglumine exerts protective effects against features of metabolic syndrome and type II diabetes. Plos One. 9: e90031. PMID 24587200 DOI: 10.1371/Journal.Pone.0090031 |
0.713 |
|
| 2014 |
Merlo LM, Pigott E, DuHadaway JB, Grabler S, Metz R, Prendergast GC, Mandik-Nayak L. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. Journal of Immunology (Baltimore, Md. : 1950). 192: 2082-90. PMID 24489090 DOI: 10.4049/Jimmunol.1303012 |
0.373 |
|
| 2014 |
Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LM, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. International Immunology. 26: 357-67. PMID 24402311 DOI: 10.1093/Intimm/Dxt073 |
0.34 |
|
| 2014 |
Trabanelli S, Očadlíková D, Ciciarello M, Salvestrini V, Lecciso M, Jandus C, Metz R, Evangelisti C, Laury-Kleintop L, Romero P, Prendergast GC, Curti A, Lemoli RM. The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 192: 1231-40. PMID 24391212 DOI: 10.4049/Jimmunol.1300720 |
0.331 |
|
| 2014 |
Thomas S, DuHadaway J, Prendergast GC, Laury-Kleintop L. Specific in situ detection of murine indoleamine 2, 3-dioxygenase. Journal of Cellular Biochemistry. 115: 391-6. PMID 24123235 DOI: 10.1002/Jcb.24674 |
0.617 |
|
| 2014 |
Muller AJ, Smith C, Chang MY, DuHadaway J, Mondal A, Flick H, Parker K, Beury D, Ostrand-Rosenberg S, Prendergast GC. Abstract 3665: IDO1 is an integrative determinant of tumor-promoting, pathogenic inflammation Cancer Research. 74: 3665-3665. DOI: 10.1158/1538-7445.Am2014-3665 |
0.38 |
|
| 2014 |
Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ. IDO in inflammatory programming and immune suppression in cancer Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal. 311-346. DOI: 10.1007/978-1-4899-8056-4_11 |
0.555 |
|
| 2013 |
Gerald D, Adini I, Shechter S, Perruzzi C, Varnau J, Hopkins B, Kazerounian S, Kurschat P, Blachon S, Khedkar S, Bagchi M, Sherris D, Prendergast GC, Klagsbrun M, Stuhlmann H, et al. RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription. Nature Communications. 4: 2824. PMID 24280686 DOI: 10.1038/Ncomms3824 |
0.351 |
|
| 2013 |
Simionescu-Bankston A, Leoni G, Wang Y, Pham PP, Ramalingam A, DuHadaway JB, Faundez V, Nusrat A, Prendergast GC, Pavlath GK. The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis. Developmental Biology. 382: 160-71. PMID 23872330 DOI: 10.1016/J.Ydbio.2013.07.004 |
0.784 |
|
| 2013 |
Kazerounian S, Gerald D, Huang M, Chin YR, Udayakumar D, Zheng N, O'Donnell RK, Perruzzi C, Mangiante L, Pourat J, Phung TL, Bravo-Nuevo A, Shechter S, McNamara S, Duhadaway JB, ... ... Prendergast GC, et al. RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Research. 73: 50-61. PMID 23135917 DOI: 10.1158/0008-5472.Can-11-3055 |
0.775 |
|
| 2013 |
Li J, Ward KM, Zhang D, Dayanandam E, Denittis AS, Prendergast GC, Ayene IS. A bioactive probe of the oxidative pentose phosphate cycle: novel strategy to reverse radioresistance in glucose deprived human colon cancer cells. Toxicology in Vitro : An International Journal Published in Association With Bibra. 27: 367-77. PMID 22926048 DOI: 10.1016/J.Tiv.2012.08.012 |
0.35 |
|
| 2013 |
Smith C, Prendergast GC. Inflammatory programming and immune modulation in cancer by IDO Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/51878 |
0.359 |
|
| 2013 |
Kunkel EK, DuHadaway J, Sutanto-Ward E, Birnhak LN, Ringqvist JR, Ali ZA, Gilman PB, Prendergast GC, Wallon UM. Abstract B070: TIMP-4 – prognostic marker and treatment target for triple-negative breast cancers Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-B070 |
0.386 |
|
| 2012 |
Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 1: 1460-1468. PMID 23264892 DOI: 10.4161/Onci.21716 |
0.353 |
|
| 2012 |
Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, Duhadaway JB, Goossens V, Roelandt R, Van Hauwermeiren F, Libert C, Declercq W, Callewaert N, Prendergast GC, Degterev A, Yuan J, et al. Necrostatin-1 analogues: Critical issues on the specificity, activity and in vivo use in experimental disease models Cell Death and Disease. 3. PMID 23190609 DOI: 10.1038/Cddis.2012.176 |
0.322 |
|
| 2012 |
Janson C, Kasahara N, Prendergast GC, Colicelli J. RIN3 is a negative regulator of mast cell responses to SCF. Plos One. 7: e49615. PMID 23185384 DOI: 10.1371/Journal.Pone.0049615 |
0.423 |
|
| 2012 |
Prendergast GC, Metz R. A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies. Oncoimmunology. 1: 924-929. PMID 23162760 DOI: 10.4161/Onci.21358 |
0.305 |
|
| 2012 |
McGaha TL, Huang L, Lemos H, Metz R, Mautino M, Prendergast GC, Mellor AL. Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunological Reviews. 249: 135-57. PMID 22889220 DOI: 10.1111/J.1600-065X.2012.01149.X |
0.306 |
|
| 2012 |
Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discovery. 2: 722-35. PMID 22822050 DOI: 10.1158/2159-8290.Cd-12-0014 |
0.344 |
|
| 2012 |
Trabanelli S, Ocadlikova D, Ciciarello M, Salvestrini V, Evangelisti C, Metz R, Laury-Kleintop L, Prendergast G, Curti A, Lemoli RM. Human Blood Dendritic Cells Induce Tregs Through the PGE2-Independent Expression of an Active Form of IDO2 Enzyme Blood. 120: 1047-1047. DOI: 10.1182/Blood.V120.21.1047.1047 |
0.323 |
|
| 2012 |
Smith C, Chang M, Flick H, DuHadaway J, Mandik-Nayak L, Laury-Kleintop L, Parker K, Beury D, Ostrand-Rosenberg S, Prendergast GC, Muller AJ. Abstract 295: IDO drives tumor-promoting, pathogenic inflammation in lung Cancer Research. 72: 295-295. DOI: 10.1158/1538-7445.Am2012-295 |
0.35 |
|
| 2011 |
Ha NH, Nair VS, Reddy DN, Mudvari P, Ohshiro K, Ghanta KS, Pakala SB, Li DQ, Costa L, Lipton A, Badwe RA, Fuqua S, Wallon M, Prendergast GC, Kumar R. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Research. 71: 7259-69. PMID 22006997 DOI: 10.1158/0008-5472.Can-11-1143 |
0.303 |
|
| 2011 |
Prendergast GC. Cancer: Why tumours eat tryptophan. Nature. 478: 192-4. PMID 21993754 DOI: 10.1038/478192A |
0.354 |
|
| 2011 |
Zhang C, Elkahloun AG, Liao H, Delaney S, Saber B, Morrow B, Prendergast GC, Hollander MC, Gills JJ, Dennis PA. Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Molecular Cancer Therapeutics. 10: 1137-48. PMID 21551261 DOI: 10.1158/1535-7163.Mct-10-1028 |
0.402 |
|
| 2011 |
Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Current Medicinal Chemistry. 18: 2257-62. PMID 21517753 DOI: 10.2174/092986711795656072 |
0.325 |
|
| 2011 |
Huang M, Satchell L, Duhadaway JB, Prendergast GC, Laury-Kleintop LD. RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. Journal of Cellular Biochemistry. 112: 1572-84. PMID 21344485 DOI: 10.1002/Jcb.23069 |
0.351 |
|
| 2011 |
Bravo-Nuevo A, Sugimoto H, Iyer S, Fallon Z, Lucas JM, Kazerounian S, Prendergast GC, Kalluri R, Shapiro NI, Benjamin LE. RhoB loss prevents streptozotocin-induced diabetes and ameliorates diabetic complications in mice. The American Journal of Pathology. 178: 245-52. PMID 21224061 DOI: 10.1016/J.Ajpath.2010.11.040 |
0.726 |
|
| 2011 |
Trabanelli S, Curti A, Ocadlikova D, Evangelisti C, Salvestrini V, Ciciarello M, Aluigi M, Rossi L, Metz R, Laury-Kleintop L, Prendergast G, Lemoli RM. PGE2-Independent Expression of Indoleamine 2,3-Dioxygenase-2 (IDO2) Supports the Tolerogenic Function of Monocyte-Derived Dendritic Cells, Blood. 118: 3231-3231. DOI: 10.1182/Blood.V118.21.3231.3231 |
0.331 |
|
| 2010 |
Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, Soler AP, Mandik-Nayak L, Gilmour SK, Prendergast GC. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunology, Immunotherapy : Cii. 59: 1655-63. PMID 20640572 DOI: 10.1007/S00262-010-0891-4 |
0.799 |
|
| 2010 |
Muller AJ, Mandik-Nayak L, Prendergast GC. Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy. 2: 293-7. PMID 20635895 DOI: 10.2217/Imt.10.22 |
0.348 |
|
| 2010 |
Metz R, Duhadaway JB, Rust S, Munn DH, Muller AJ, Mautino M, Prendergast GC. Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Molecular Cancer Therapeutics. 9: 1864-71. PMID 20530717 DOI: 10.1158/1535-7163.Mct-10-0185 |
0.373 |
|
| 2010 |
Prendergast GC, Metz R, Muller AJ. Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. The American Journal of Pathology. 176: 2082-7. PMID 20228228 DOI: 10.2353/Ajpath.2010.091173 |
0.345 |
|
| 2010 |
Ciorba MA, Bettonville EE, McDonald KG, Metz R, Prendergast GC, Newberry RD, Stenson WF. Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. Journal of Immunology (Baltimore, Md. : 1950). 184: 3907-16. PMID 20181893 DOI: 10.4049/Jimmunol.0900291 |
0.344 |
|
| 2010 |
Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC. Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Research. 70: 1845-53. PMID 20160032 DOI: 10.1158/0008-5472.Can-09-3613 |
0.381 |
|
| 2010 |
Trabanelli S, Curti A, Očadlíková D, Evangelisti C, Salvestrini V, Metz R, Laury-Kleintop L, Prendergast G, Lemoli RM. Human Monocyte-Derived Dendritic Cells Are Tolerogenic through Both IDO1 and IDO2 Blood. 116: 4298-4298. DOI: 10.1182/Blood.V116.21.4298.4298 |
0.305 |
|
| 2010 |
Ward KM, Li J, Zhang D, Dayanandam E, DeNittis AS, Prendergast GC, Ayene IS. Abstract 1392: HEDS selectively radiosensitizes human cancer cells in glucose-deprived environments via inhibition of Ku protein function Cancer Research. 70: 1392-1392. DOI: 10.1158/1538-7445.Am10-1392 |
0.341 |
|
| 2010 |
Muller AJ, DuHadaway JB, Chang MY, Soler AP, Prendergast GC. Abstract 1347: Immune escape mediator IDO is a crucial defining element of ‘cancer-associated’ inflammation in the tumor microenvironment Cancer Research. 70: 1347-1347. DOI: 10.1158/1538-7445.Am10-1347 |
0.401 |
|
| 2009 |
DeWard AD, Leali K, West RA, Prendergast GC, Alberts AS. Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice. Plos One. 4: e7102. PMID 19768111 DOI: 10.1371/Journal.Pone.0007102 |
0.321 |
|
| 2009 |
Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. Journal of Immunology (Baltimore, Md. : 1950). 182: 7509-17. PMID 19494274 DOI: 10.4049/Jimmunol.0804328 |
0.38 |
|
| 2009 |
Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. Journal of the American College of Surgeons. 208: 781-7; discussion 78. PMID 19476837 DOI: 10.1016/J.Jamcollsurg.2008.12.018 |
0.342 |
|
| 2009 |
Prendergast GC, Muller AJ, Ramalingam A, Chang MY. BAR the door: cancer suppression by amphiphysin-like genes. Biochimica Et Biophysica Acta. 1795: 25-36. PMID 18930786 DOI: 10.1016/J.Bbcan.2008.09.001 |
0.808 |
|
| 2009 |
Dalenc F, Filleron T, Keller L, Meunier, Malissein, Bergé Y, Roché H, Favre G, Prendergast G, Lacroix-Triki M, Doisneau-sixou S. Correlation between RhoB and Estrogen Receptor α (ERα) Expressions: From Experimental Data to Human Breast Tumors. Cancer Research. 69: 5146-5146. DOI: 10.1158/0008-5472.Sabcs-09-5146 |
0.324 |
|
| 2008 |
Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proceedings of the National Academy of Sciences of the United States of America. 105: 17073-8. PMID 18952840 DOI: 10.1073/Pnas.0806173105 |
0.369 |
|
| 2008 |
Chien J, Narita K, Rattan R, Giri S, Shridhar R, Staub J, Beleford D, Lai J, Roberts LR, Molina J, Kaufmann SH, Prendergast GC, Shridhar V. A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation Oncogene. 27: 7223-7234. PMID 18806825 DOI: 10.1038/Onc.2008.360 |
0.424 |
|
| 2008 |
Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunological Reviews. 222: 206-21. PMID 18364004 DOI: 10.1111/J.1600-065X.2008.00610.X |
0.387 |
|
| 2008 |
Ramalingam A, Duhadaway JB, Sutanto-Ward E, Wang Y, Dinchuk J, Huang M, Donover PS, Boulden J, McNally LM, Soler AP, Muller AJ, Duncan MK, Prendergast GC. Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging. Cancer Research. 68: 1683-90. PMID 18339847 DOI: 10.1158/0008-5472.Can-07-6072 |
0.802 |
|
| 2008 |
Kumar S, Malachowski WP, DuHadaway JB, LaLonde JM, Carroll PJ, Jaller D, Metz R, Prendergast GC, Muller AJ. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. Journal of Medicinal Chemistry. 51: 1706-18. PMID 18318466 DOI: 10.1021/Jm7014155 |
0.306 |
|
| 2008 |
Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene. 27: 3889-900. PMID 18317452 DOI: 10.1038/Onc.2008.35 |
0.362 |
|
| 2008 |
Li Z, Wang C, Jiao X, Katiyar S, Casimiro MC, Prendergast GC, Powell MJ, Pestell RG. Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. The Journal of Biological Chemistry. 283: 7007-15. PMID 18180298 DOI: 10.1074/Jbc.M706992200 |
0.363 |
|
| 2008 |
Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene. 27: 2851-7. PMID 18026137 DOI: 10.1038/Sj.Onc.1210939 |
0.364 |
|
| 2008 |
Meunier E, Malissein E, Bouliong-Pillai E, Bergé Y, Balaguer P, Prendergast G, Favre G, Dalenc F, Doisneau-Sixou S. 580 POSTER RhoA and RhoB inversly modulate estrogen receptor alpha expression and transcriptional activities in breast cancer cell lines European Journal of Cancer Supplements. 6: 182. DOI: 10.1016/S1359-6349(08)72514-X |
0.302 |
|
| 2007 |
Kamasani U, Duhadaway JB, Alberts AS, Prendergast GC. mDia function is critical for the cell suicide program triggered by farnesyl transferase inhibition. Cancer Biology & Therapy. 6: 1422-7. PMID 17786040 DOI: 10.4161/Cbt.6.9.4546 |
0.425 |
|
| 2007 |
Chang MY, Boulden J, Katz JB, Wang L, Meyer TJ, Soler AP, Muller AJ, Prendergast GC. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Research. 67: 7605-12. PMID 17699764 DOI: 10.1158/0008-5472.Can-07-1100 |
0.329 |
|
| 2007 |
Ramalingam A, Farmer GE, Stamato TD, Prendergast GC. Bin1 interacts with and restrains the DNA end-binding protein complex Ku. Cell Cycle (Georgetown, Tex.). 6: 1914-8. PMID 17671430 DOI: 10.4161/Cc.6.15.4514 |
0.793 |
|
| 2007 |
Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Research. 67: 7082-7. PMID 17671174 DOI: 10.1158/0008-5472.Can-07-1872 |
0.356 |
|
| 2007 |
Ramalingam A, Prendergast GC. Bin1 homolog hob1 supports a Rad6-Set1 pathway of transcriptional repression in fission yeast. Cell Cycle (Georgetown, Tex.). 6: 1655-62. PMID 17611416 DOI: 10.4161/Cc.6.13.4413 |
0.811 |
|
| 2007 |
Prendergast GC, Jaffee EM. Cancer immunologists and cancer biologists: why we didn't talk then but need to now. Cancer Research. 67: 3500-4. PMID 17413003 DOI: 10.1158/0008-5472.Can-06-4626 |
0.399 |
|
| 2007 |
Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Current Cancer Drug Targets. 7: 31-40. PMID 17305476 DOI: 10.2174/156800907780006896 |
0.394 |
|
| 2007 |
Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Research. 67: 792-801. PMID 17234791 DOI: 10.1158/0008-5472.Can-06-2925 |
0.372 |
|
| 2007 |
Ghaneie A, Zemba-Palko V, Itoh H, Itoh K, Sakamuro D, Nakamura S, Soler AP, Prendergast GC. Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biology & Therapy. 6: 192-4. PMID 17218774 DOI: 10.4161/Cbt.6.2.3587 |
0.683 |
|
| 2007 |
Chang MY, Boulden J, Sutanto-Ward E, Duhadaway JB, Soler AP, Muller AJ, Prendergast GC. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Research. 67: 100-7. PMID 17210688 DOI: 10.1158/0008-5472.Can-06-2742 |
0.405 |
|
| 2006 |
Li Z, Wang C, Prendergast GC, Pestell RG. Cyclin D1 functions in cell migration. Cell Cycle (Georgetown, Tex.). 5: 2440-2. PMID 17106256 DOI: 10.4161/Cc.5.21.3428 |
0.404 |
|
| 2006 |
Huang M, Kamasani U, Prendergast GC. RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3. Oncogene. 25: 1281-9. PMID 16247449 DOI: 10.1038/Sj.Onc.1209174 |
0.367 |
|
| 2005 |
Muller AJ, Malachowski WP, Prendergast GC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opinion On Therapeutic Targets. 9: 831-49. PMID 16083346 DOI: 10.1517/14728222.9.4.831 |
0.328 |
|
| 2005 |
Kamasani U, Prendergast GC. Genetic response to DNA damage: proapoptotic targets of RhoB include modules for p53 response and susceptibility to Alzheimer's disease. Cancer Biology & Therapy. 4: 282-8. PMID 15876868 DOI: 10.4161/Cbt.4.3.1498 |
0.39 |
|
| 2005 |
Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine. 11: 312-9. PMID 15711557 DOI: 10.1038/Nm1196 |
0.405 |
|
| 2005 |
Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. Plos Medicine. 2: e18. PMID 15647781 DOI: 10.1371/Journal.Pmed.0020018 |
0.316 |
|
| 2004 |
Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biology & Therapy. 3: 1236-42. PMID 15611650 DOI: 10.4161/Cbt.3.12.1232 |
0.434 |
|
| 2004 |
Kamasani U, Huang M, Duhadaway JB, Prochownik EV, Donover PS, Prendergast GC. Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Research. 64: 8389-96. PMID 15548709 DOI: 10.1158/0008-5472.Can-04-2437 |
0.375 |
|
| 2003 |
Adini I, Rabinovitz I, Sun JF, Prendergast GC, Benjamin LE. RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes & Development. 17: 2721-32. PMID 14597666 DOI: 10.1101/Gad.1134603 |
0.359 |
|
| 2003 |
Prendergast GC. Signal transduction: putting translation before transcription. Cancer Cell. 4: 244-5. PMID 14585349 DOI: 10.1016/S1535-6108(03)00247-2 |
0.31 |
|
| 2003 |
Kamasani U, Liu AX, Prendergast GC. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biology & Therapy. 2: 273-80. PMID 12878865 DOI: 10.4161/Cbt.2.3.385 |
0.704 |
|
| 2003 |
DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene. 22: 3578-88. PMID 12789266 DOI: 10.1038/Sj.Onc.1206481 |
0.718 |
|
| 2003 |
Muller AJ, Baker JF, DuHadaway JB, Ge K, Farmer G, Donover PS, Meade R, Reid C, Grzanna R, Roach AH, Shah N, Soler AP, Prendergast GC. Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Molecular and Cellular Biology. 23: 4295-306. PMID 12773571 DOI: 10.1128/Mcb.23.12.4295-4306.2003 |
0.568 |
|
| 2003 |
Zeng PY, Rane N, Du W, Chintapalli J, Prendergast GC. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene. 22: 1124-34. PMID 12606940 DOI: 10.1038/Sj.Onc.1206181 |
0.418 |
|
| 2003 |
Routhier EL, Donover PS, Prendergast GC. hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress. Oncogene. 22: 637-48. PMID 12569356 DOI: 10.1038/sj.onc.1206162 |
0.795 |
|
| 2003 |
DuHadaway JB, Lynch FJ, Brisbay S, Bueso-Ramos C, Troncoso P, McDonnell T, Prendergast GC. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. Journal of Cellular Biochemistry. 88: 635-42. PMID 12532338 DOI: 10.1002/Jcb.10380 |
0.364 |
|
| 2002 |
Prendergast GC. Farnesyltransferase inhibitors: potential therapeutic for inflammatory breast cancer? Breast Disease. 15: 25-32. PMID 15687643 DOI: 10.3233/Bd-2002-15104 |
0.389 |
|
| 2002 |
Prendergast GC. CHK and MEK inhibitors team up to trigger cancer cell suicide. Cancer Biology & Therapy. 1: 254-5. PMID 12432272 DOI: 10.4161/Cbt.76 |
0.318 |
|
| 2002 |
Zhang B, Prendergast GC, Fenton RG. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Research. 62: 450-8. PMID 11809695 |
0.301 |
|
| 2002 |
Prendergast GC, Rane N. Farnesyltransferase inhibitors: mechanism and applications. Expert Opinion On Investigational Drugs. 10: 2105-16. PMID 11772308 DOI: 10.1517/13543784.10.12.2105 |
0.41 |
|
| 2001 |
Liu AX, Rane N, Liu JP, Prendergast GC. RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Molecular and Cellular Biology. 21: 6906-12. PMID 11564874 DOI: 10.1128/Mcb.21.20.6906-6912.2001 |
0.679 |
|
| 2001 |
Liu Ax, Cerniglia GJ, Bernhard EJ, Prendergast GC. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proceedings of the National Academy of Sciences of the United States of America. 98: 6192-7. PMID 11353846 DOI: 10.1073/Pnas.111137198 |
0.404 |
|
| 2001 |
DuHadaway JB, Sakamuro D, Ewert DL, Prendergast GC. Bin1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Research. 61: 3151-6. PMID 11306501 |
0.712 |
|
| 2001 |
Routhier EL, Burn TC, Abbaszade I, Summers M, Albright CF, Prendergast GC. Human BIN3 complements the F-actin localization defects caused by loss of Hob3p, the fission yeast homolog of Rvs161p. The Journal of Biological Chemistry. 276: 21670-7. PMID 11274158 DOI: 10.1074/Jbc.M101096200 |
0.769 |
|
| 2001 |
Prendergast GC. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology. Histology and Histopathology. 16: 269-75. PMID 11193202 DOI: 10.14670/HH-16.269 |
0.338 |
|
| 2001 |
Prendergast GC, Oliff A. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. Seminars in Cancer Biology. 10: 443-52. PMID 11170866 DOI: 10.1006/SCBI.2000.0335 |
0.3 |
|
| 2000 |
Elliott K, Ge K, Du W, Prendergast GC. The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program. Oncogene. 19: 4669-84. PMID 11032017 DOI: 10.1038/Sj.Onc.1203681 |
0.619 |
|
| 2000 |
Liu A, Prendergast GC. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors. Febs Letters. 481: 205-8. PMID 11007964 DOI: 10.1016/S0014-5793(00)02003-2 |
0.656 |
|
| 2000 |
Liu Ax, Du W, Liu JP, Jessell TM, Prendergast GC. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Molecular and Cellular Biology. 20: 6105-13. PMID 10913192 DOI: 10.1128/Mcb.20.16.6105-6113.2000 |
0.696 |
|
| 2000 |
Ge K, Prendergast GC. Bin2, a functionally nonredundant member of the BAR adaptor gene family. Genomics. 67: 210-20. PMID 10903846 DOI: 10.1006/Geno.2000.6216 |
0.581 |
|
| 2000 |
Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, Sakamuro D, Nelson P, Malkowicz SB, Tomaszewski J, Prendergast GC. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. International Journal of Cancer. 86: 155-61. PMID 10738240 DOI: 10.1002/(Sici)1097-0215(20000415)86:2<155::Aid-Ijc2>3.0.Co;2-M |
0.756 |
|
| 2000 |
Prendergast GC. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Current Opinion in Cell Biology. 12: 166-73. PMID 10712917 DOI: 10.1016/S0955-0674(99)00072-1 |
0.357 |
|
| 2000 |
Ge K, Duhadaway J, Sakamuro D, Wechsler-Reya R, Reynolds C, Prendergast GC. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity International Journal of Cancer. 85: 376-383. PMID 10652430 DOI: 10.1002/(Sici)1097-0215(20000201)85:3<376::Aid-Ijc14>3.0.Co;2-1 |
0.797 |
|
| 1999 |
Prendergast GC, Du W. Targeting farnesyltransferase: is Ras relevant? Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2: 81-84. PMID 11504474 DOI: 10.1054/Drup.1999.0070 |
0.37 |
|
| 1999 |
Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proceedings of the National Academy of Sciences of the United States of America. 96: 9689-94. PMID 10449755 DOI: 10.1073/Pnas.96.17.9689 |
0.648 |
|
| 1999 |
Duhadaway J, Rowe F, Elliott K, Mao NC, Prendergast GC. Bau, a splice form of Neurabin-I that interacts with the tumor suppressor Bin1, inhibits malignant cell transformation. Cell Adhesion and Communication. 7: 99-110. PMID 10427963 DOI: 10.3109/15419069909034394 |
0.436 |
|
| 1999 |
Elliott K, Sakamuro D, Basu A, Du W, Wunner W, Staller P, Gaubatz S, Zhang H, Prochownik E, Eilers M, Prendergast GC. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene. 18: 3564-73. PMID 10380878 DOI: 10.1038/Sj.Onc.1202670 |
0.735 |
|
| 1999 |
Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene. 18: 2967-87. PMID 10378693 DOI: 10.1038/Sj.Onc.1202727 |
0.362 |
|
| 1999 |
Sakamuro D, Prendergast GC. New Myc-interacting proteins: a second Myc network emerges. Oncogene. 18: 2942-54. PMID 10378691 DOI: 10.1038/Sj.Onc.1202725 |
0.72 |
|
| 1999 |
Megyeri K, Berencsi K, Halazonetis TD, Prendergast GC, Gri G, Plotkin SA, Rovera G, Gönczöl E. Involvement of a p53-dependent pathway in rubella virus-induced apoptosis. Virology. 259: 74-84. PMID 10364491 DOI: 10.1006/Viro.1999.9757 |
0.319 |
|
| 1999 |
Du W, Lebowitz PF, Prendergast GC. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors. Cancer Research. 59: 2059-63. PMID 10232587 |
0.694 |
|
| 1999 |
Mao NC, Steingrimsson E, DuHadaway J, Wasserman W, Ruiz JC, Copeland NG, Jenkins NA, Prendergast GC. The murine Bin1 gene functions early in myogenesis and defines a new region of synteny between mouse chromosome 18 and human chromosome 2. Genomics. 56: 51-8. PMID 10036185 DOI: 10.1006/Geno.1998.5709 |
0.342 |
|
| 1999 |
Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Molecular and Cellular Biology. 19: 1831-40. PMID 10022870 DOI: 10.1128/Mcb.19.3.1831 |
0.756 |
|
| 1998 |
Lebowitz PF, Prendergast GC. Functional interaction between RhoB and the transcription factor DB1. Cell Adhesion and Communication. 6: 277-87. PMID 9865462 DOI: 10.3109/15419069809010787 |
0.729 |
|
| 1998 |
Lebowitz PF, Prendergast GC. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 17: 1439-45. PMID 9779989 DOI: 10.1038/Sj.Onc.1202175 |
0.759 |
|
| 1998 |
Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, ... ... Prendergast GC, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 16: 1097-112. PMID 9528852 DOI: 10.1038/Sj.Onc.1201861 |
0.377 |
|
| 1998 |
Wechsler-Reya RJ, Elliott KJ, Prendergast GC. A role for the putative tumor suppressor Bin1 in muscle cell differentiation. Molecular and Cellular Biology. 18: 566-75. PMID 9418903 DOI: 10.1128/Mcb.18.1.566 |
0.603 |
|
| 1997 |
Wechsler-Reya R, Sakamuro D, Zhang J, Duhadaway J, Prendergast GC. Structural analysis of the human BIN1 gene: Evidence for tissue-specific transcriptional regulation and alternate RNA splicing Journal of Biological Chemistry. 272: 31453-31458. PMID 9395479 DOI: 10.1074/Jbc.272.50.31453 |
0.764 |
|
| 1997 |
Sakamuro D, Sabbatini P, White E, Prendergast GC. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene. 15: 887-98. PMID 9285684 DOI: 10.1038/Sj.Onc.1201263 |
0.732 |
|
| 1997 |
Lebowitz PF, Du W, Prendergast GC. Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription. The Journal of Biological Chemistry. 272: 16093-5. PMID 9195903 DOI: 10.1074/Jbc.272.26.16093 |
0.739 |
|
| 1997 |
Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. The Journal of Biological Chemistry. 272: 15591-4. PMID 9188444 DOI: 10.1074/Jbc.272.25.15591 |
0.754 |
|
| 1997 |
Lebowitz PF, Sakamuro D, Prendergast GC. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Research. 57: 708-13. PMID 9044849 |
0.808 |
|
| 1996 |
Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor Nature Genetics. 14: 69-77. PMID 8782822 DOI: 10.1038/Ng0996-69 |
0.785 |
|
| 1996 |
Negorev D, Riethman H, Wechsler-Reya R, Sakamuro D, Prendergast GC, Simon D. The Bin1 gene localizes to human chromosome 2q14 by PCR analysis of somatic cell hybrids and fluorescence in situ hybridization Genomics. 33: 329-331. PMID 8725406 DOI: 10.1006/Geno.1996.0205 |
0.737 |
|
| 1996 |
Negorev D, Riethman H, Wechsler-Reya R, Sakamuro D, Prendergast GC, Simon D. The Bin1 Gene Localizes to Human Chromosome 2q14 by PCR Analysis of Somatic Cell Hybrids and Fluorescence in Situ Hybridization Genomics. 33: 329-31. PMID 8660989 |
0.648 |
|
| 1996 |
Prendergast GC, Davide JP, Lebowitz PF, Wechsler-Reya R, Kohl NE. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors Cancer Research. 56: 2626-2632. PMID 8653708 |
0.757 |
|
| 1995 |
Sakamuro D, Eviner V, Elliott KJ, Showe L, White E, Prendergast GC. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms Oncogene. 11: 2410-2418. PMID 8570193 |
0.69 |
|
| 1995 |
Lebowitz PF, Davide JP, Prendergast GC. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Molecular and Cellular Biology. 15: 6613-22. PMID 8524226 DOI: 10.1128/Mcb.15.12.6613 |
0.728 |
|
| 1995 |
Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF, Der CJ. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene. 10: 2289-96. PMID 7784077 |
0.715 |
|
| 1994 |
Prendergast GC, Davide JP, deSolms SJ, Giuliani EA, Graham SL, Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Molecular and Cellular Biology. 14: 4193-202. PMID 8196657 DOI: 10.1128/Mcb.14.6.4193 |
0.383 |
|
| 1994 |
Prendergast GC, Gibbs JB. Ras regulatory interactions: novel targets for anti-cancer intervention? Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 16: 187-91. PMID 8166672 DOI: 10.1002/Bies.950160309 |
0.351 |
|
| 1994 |
Prendergast GC, Gibbs JB. Pathways of Ras function: connections to the actin cytoskeleton. Advances in Cancer Research. 62: 19-64. PMID 8109319 DOI: 10.1016/S0065-230X(08)60314-0 |
0.344 |
|
| 1994 |
Li L, Nerlov C, Prendergast G, Macgregor D, Ziff EB. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. The Embo Journal. 13: 4070-4079. DOI: 10.1002/J.1460-2075.1994.Tb06724.X |
0.387 |
|
| 1993 |
Ferré-D'Amaré AR, Prendergast GC, Ziff EB, Burley SK. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. Nature. 363: 38-45. PMID 8479534 DOI: 10.1038/363038A0 |
0.519 |
|
| 1992 |
Prendergast GC, Ziff EB. A new bind for Myc. Trends in Genetics : Tig. 8: 91-6. PMID 1579994 DOI: 10.1016/0168-9525(92)90196-B |
0.506 |
|
| 1992 |
Prendergast GC, Hopewell R, Gorham BJ, Ziff EB. Biphasic effect of Max on Myc cotransformation activity and dependence on amino- and carboxy-terminal Max functions. Genes & Development. 6: 2429-39. PMID 1459463 DOI: 10.1101/Gad.6.12A.2429 |
0.608 |
|
| 1991 |
Prendergast GC, Ziff EB. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science (New York, N.Y.). 251: 186-9. PMID 1987636 DOI: 10.1126/Science.1987636 |
0.568 |
|
| 1991 |
Prendergast GC, Ziff EB. Mbh 1: a novel gelsolin/severin-related protein which binds actin in vitro and exhibits nuclear localization in vivo. The Embo Journal. 10: 757-66. PMID 1849072 DOI: 10.1002/J.1460-2075.1991.Tb08007.X |
0.59 |
|
| 1991 |
Prendergast GC, Lawe D, Ziff EB. Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation. Cell. 65: 395-407. PMID 1840505 DOI: 10.1016/0092-8674(91)90457-A |
0.577 |
|
| 1990 |
Prendergast GC, Diamond LE, Dahl D, Cole MD. The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Molecular and Cellular Biology. 10: 1265-9. PMID 2406566 |
0.501 |
|
| 1989 |
Prendergast GC, Ziff EB. DNA-binding motif. Nature. 341: 392. PMID 2507924 DOI: 10.1038/341392a0 |
0.462 |
|
| 1989 |
Prendergast GC, Cole MD. Posttranscriptional regulation of cellular gene expression by the c-myc oncogene. Molecular and Cellular Biology. 9: 124-34. PMID 2467185 |
0.507 |
|
| Show low-probability matches. |